

Amendment List
Prescription Drug Pricing Reduction Act of 2019
July 25, 2019

Committee Number	Senator	Summary	Off-Set
1	Grassley #1	To be supplied	
2	Grassley #2	To be supplied	
3	Roberts #1	Using Market Forces to Keep Drug Prices Low	
4	Roberts #2	Encouraging Stable Premiums for Medicare Part D Beneficiaries	
5	Roberts #3	Three Rationers Repeal	
6	Roberts #4	Improving Metrics for Price Reporting for Orphan Drugs Act	
7	Cornyn/Cardin #1	Preventing Fraud in Medicare Part D	To be Provided
8	Cornyn #2	Improving Innovation in Dialysis Treatment	To be Provided
9	Cornyn #3	Clarification of Negotiated Price Definition	To be Provided
10	Cornyn #4	Expanding Access to Generics and Biosimilars	To be Provided
11	Cornyn #5	Protecting Seniors from High Drug Prices	To be Provided
12	Thune #1	To lower prescription drug costs and support competition and free market principles	To be Provided
13	Thune/Enzi #2	To support reducing beneficiary out of pocket costs and premiums and deficit reduction	To be Provided
14	Thune #3	TBD	TBD
15	Thune #4	TBD	TBD
16	Thune/Carper #5	To further promote value-based insurance design in Medicare Advantage and Part D	
17	Thune/Carper #6	Chronic Disease Management Act	To be Provided
18	Burr/Bennet/Scott/Carper #1	To improve the coordination between the U.S. Food and Drug Administration and the Centers for Medicare and Medicaid Services (CMS)	To be Provided
19	Portman #1	Require that Prescription Drug Plans to pass along an increased amount of rebates to patients at the point of sale. Increased amounts of rebates would be defined as the greater of either 20% of all total rebates collected or 20% more rebates than a Prescription Drug Plan had passed along to patients at the point of sale in plan year 2019.	

Amendment List
Prescription Drug Pricing Reduction Act of 2019
July 25, 2019

20	Portman/Carper #2	Require HHS to conduct a study on the influence of pharmaceutical manufacturer distribution models that provide third-party reimbursement hub services on health care providers who prescribe the manufacturer's drugs.	
21	Toomey/Roberts #1	To strike section 128 from the Prescription Drug Pricing Reduction Act (PDPRA) of 2019	To be Provided if Necessary
22	Toomey #2	To strike Section 107 of the Prescription Drug Pricing Reduction Act (PDPRA) of 2019	To be Provided if Necessary
23	Toomey #3	To strike Section 209 of the Prescription Drug Pricing Reduction Act (PDPRA) of 2019	To be Provided if Necessary
24	Toomey #4	To prevent drug prices from increasing as a result of this legislation	
25	Toomey #5	To ensure transparency and a robust fiscal analysis of the Prescription Drug Pricing Reduction Act (PDPRA) of 2019	
26	Toomey #6	To prohibit the International Pricing Index Model for Medicare Part B Drugs subject to Section 107 of the Prescription Drug Pricing Reduction Act (PDPRA) of 2019.	
27	Toomey #7	To increase accountability and transparency in the Federal regulatory process by applying the provisions of the Regulations from the Executive in Need of Scrutiny (REINS) Act (S. 92) to the Prescription Drug Pricing Reduction Act (PDPRA) of 2019	
28	Toomey #8	To amend the Internal Revenue Code of 1986 to restore incentives for investments in qualified improvement property.	Has no Cost
29	Toomey #9	The Empowering State Medicaid Programs to Lower Drug Prices Act	To be Provided if Necessary
30	Toomey #10	To preserve state flexibility in contracting.	To be Provided if Necessary
31	Toomey #11	To be supplied by sponsor	
32	Toomey #12	To be supplied by sponsor	
33	Toomey #13	To be supplied by sponsor	

Amendment List
 Prescription Drug Pricing Reduction Act of 2019
 July 25, 2019

34	Toomey #14	To be supplied by sponsor	
35	Toomey/Crapo #15	To allow for the offering of additional standalone Medicare prescription drug plans and increase the availability of plans offering point-of-sale rebates.	To be Determined
36	Toomey/Enzi #16	To require the Medicare Payment Advisory Commission (MedPAC) submit to Congress a report on shifting coverage of certain Medicare Part B to Medicare Part D.	No additional funds are authorized for purposes of the report
37	Cassidy #1	To ensure providers and Medicare are appropriately paid under the Average Sales Price (ASP) formula	
38	Cassidy #2	To study the difference between price reported for Average Sales Price (ASP) purposes in commercial and Medicare claims	
39	Cassidy #3	To allow Medicare and Medicaid to better avoid duplicate discounts	
40	Cassidy #4	To allow for innovation to be appropriately assessed under the Part D inflation rebate	
41	Cassidy #5	To Ensure Equity for Rare Disease Patients	To be Provided
42	Cassidy/Menendez #6	To add a new measure set to the Medicare Star Ratings Program encouraging biosimilar uptake	
43	Cassidy/Menendez #7	To provide relief for Medicare patients with chronic conditions	
44	Cassidy/Brown/ Lankford/ Menendez/Daines #8	To establish pharmacy quality metrics in Medicare Part D	
45	Cassidy/Brown/ Lankford/ Menendez/Daines #9	Technical Update to Bona Fide Fees Definition	
46	Wyden #1	Placeholder/TBD	TBD
47	Wyden #2	Placeholder/TBD	TBD

Amendment List
Prescription Drug Pricing Reduction Act of 2019
July 25, 2019

48	Stabenow/Wyden/ Brown/Cantwell/ Cardin/Bennet, Casey/Warner/ Whitehouse/ Hassan/Cortez Masto #1	Medicare Drug Price Negotiation	
49	Stabenow #2	TBD	
50	Stabenow #3	TBD	
51	Stabenow #4	TBD	
52	Cantwell/ Stabenow/Cardin/ Brown/Hassan #1	Requiring a report by the Secretary of Health and Human Services related to drug shortages in the Medicare program	To be Provided, if necessary
53	Cantwell#2	Lymphedema Treatment Act	To be Provided
54	Cantwell/Lankford #3	To amend title XI of the Social Security Act to strengthen and expand pharmacy benefit manager transparency requirements	To be Provided, if necessary
55	Menendez /Lankford/Cardin/ Daines#1	Incentivizing Generic and Biosimilar Use in Medicare Part D	
56	Menendez/ Lankford/Cardin/ Daines#2	Incentivizing Generic Use in Medicare Part D	
57	Menendez/Carper #3	biosimilar	
58	Carper #1	GAO report reviewing representation on patients in Medicare local coverage determination (LCD) and national coverage determination (NCD) processes	No offset needed
59	Carper #2	Medicare Advantage Insurer Pharmacy and Therapeutics (P&T) Committee Improvements	No offset needed

Amendment List
Prescription Drug Pricing Reduction Act of 2019
July 25, 2019

60	Carper #3	GAO report reviewing representation on patients in Medicare local coverage determination (LCD) and national coverage determination (NCD) processes	No offset needed
61	Carper #4	Providing Access to Medicare Part D for Medicare-only PACE enrollees	To be provided at a later date
62	Carper #5	GAO report on effect of Medicaid inflation cap on generic drugs	No offset needed
63	Cardin #1	To address drug shortages	To be provided, as needed
64	Cardin/Cornyn #2	Streamlining the Part D Appeals Process	To be provided, as needed
65	Cardin/Cortez Masto/Hassan #3	Empowering States to Address Prescription Drug Costs	To be provided, as needed
66	Cardin/Whitehouse #4	International Price Indexing	To be provided, as needed
67	Cardin-Hassan/Brown #5	Civil Monetary Penalties for Not Reporting Drugs in	To be provided, as needed
68	Cardin #6	Tax Credit For Increased Production of Drugs on the Drug Shortage List.	To be provided, as needed
69	Brown #1	Medicare Negotiations and Competitive Licensing Act (S. 377)	to be provided (if necessary, as this is expected to be a saver)
70	Brown/Hassan #2	Stop Price Gouging Act (S. 378)	to be provided (if necessary, as this is expected to be a saver)
71	Brown #3	Medicare Out of Pocket Cap	To be Provided

Amendment List
 Prescription Drug Pricing Reduction Act of 2019
 July 25, 2019

72	Brown/Hassan #4	Reinstatement of Rebates into Part D for LIS Beneficiaries	In Past years, the CBO has estimated that this provision would save \$141B over 10 yrs
73	Brown #5	Biologics Exclusivity	to be provided (if necessary, as this is expected to be a saver)
74	Brown/Stabenow #6	Rebate Requirement for High Initial Launch Price	to be provided (if necessary, as this is expected to be a saver)
75	Brown/Cardin/Hassan #7	Reduced Part D Premiums	To be Provided
76	Brown/Cardin/Hassan #8	Reduced Out of Pocket Cap in Part D	To be Provided
77	Brown/Cortez Masto/Whitehouse/Hassan #9	End Taxpayer Subsidies for Drug Ads Act (S. 73)	To be Provided
78	Brown/Cassidy/Carper/Lankford/Hassan/Daines #10	Phair Relief Act	To be Provided
79	Brown/Carper #11	Part D Negotiated Prices Required to Take Into Account All Price Concessions at the Point-Of-Sale	To be Determined

Amendment List
 Prescription Drug Pricing Reduction Act of 2019
 July 25, 2019

80	Bennet/Burr/ Carper/Scott/ Brown/Cassidy #1	Improve Coordination between the U.S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS)	
81	Casey/Cortez Masto/Brown/ Stabenow #1	Medicare Extra Rx HELP (Higher Eligibility Limits in Part D) Act	
82	Casey #2	Prescription Drug Pricing Dashboard Act	
83	Casey/Brown/Stab enow/Hassan #3	Protecting Married Seniors from Impoverishment Act	
84	Warner #1	Reducing Prescription Drug Costs for Children’s Health Insurance Program	Produces Budetary Savings
85	Warner/Carper/ Bennet #2	Providing for Independent Clinical Valuation of New and Existing Therapies	
86	Warner/Bennet#3	Technical Assistance to States Seeking to Implement Value-Based and Other Innovative Payment Arrangements	
87	Whitehouse #1	Tax Treatment of Patient Assistance Programs	
88	Whitehouse/ Brown #2	Vaccine cost-sharing under Medicare Part D	To be Provided
89	Whitehouse #3	International Pricing Index	
90	Whitehouse #4	International Pricing Index Start Date	
91	Hassan #1	Inflationary Rebate Multiplier for Price Spikes in Medicare Part B	
92	Hassan #2	Inflationary Rebate Multiplier for Price Spikes in Medicare Part D	
93	Hassan/Brown/ Cortez Masto #3	Extending the Part D Rebate Liability to Reformulated and Repackaged Products	
94	Hassan/ Whitehouse/Brow n#4	GAO Study on Increases to Medicare Spending due to Pharmaceutical Manufacturer Contributions to Copay and Patient Assistance Organizations	

Amendment List
 Prescription Drug Pricing Reduction Act of 2019
 July 25, 2019

95	Hassan/ Whitehouse/Brown#5	Requiring Patient Assistance Programs to Report Medicare Data	
96	Hassan/Cortez Masto/Whitehouse #6	Adding Samples to the Medicare Open Payments Database	
97	Hassan/ Whitehouse#7	Mandatory Reporting of Charitable Contributions by Opioid Manufacturers	
98	Hassan #8	Mandatory Reporting of Charitable Contributions by Drug Manufacturers	
99	Hassan/Brown #9	Requiring Manufacturer Compliance with Post-Market Reporting Requirements	
100	Hassan/Cortez Masto/Brown #10	Ensuring Beneficiary Certainty In Part D During the Benefit Redesign	
101	Cortez Masto/Stabenow/ Hassan/Brown #1	Reporting Government Contributions to Research and Development	
102	Cortez Masto/ Stabenow/Hassan/ Brown #2	Understanding Government Contributions to Research and Development	
103	Cortez Masto/Stabenow/ Hassan #3	Ensuring a Fair Deal for States	
104	Cortez Masto #4	Protecting Patients	
105	Cortez Masto/Hassan/ Brown #5	Ensuring Manufacturer Compliance with FDA Efficacy Safeguards	
106	Cortez Masto/Hassan #6	Ensuring a Fair Price for State Medicaid Agencies	

Amendment List
Prescription Drug Pricing Reduction Act of 2019
July 25, 2019

107	Cortez Masto/Hassan #7	Estimating the Impact of Unforeseen Circumstances on State Medicaid Agencies	
108	Cortez Masto/Warner/ Hassan #8	Understanding the Impact of the Act on List and Launch Price over Time	
109	Cortez Masto/Brown #9	Enhancing the Public Benefit of Direct to Consumer Advertising	
110	Cortez Masto #10	Taking Steps to Fulfill Treaty Obligations to Tribal Communities	

